Icure Pharmaceutical Incorporation (175250) — Cash Flow Quality Index
Icure Pharmaceutical Incorporation (175250) has a Cash Flow Quality Index of -689.55x as of December 2024. Operating cash flow of ₩-17.05 Billion is below net income of ₩24.73 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 175250 long-term investments to assets to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Icure Pharmaceutical Incorporation Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for Icure Pharmaceutical Incorporation across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 175250 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Icure Pharmaceutical Incorporation (2017–2024)
Year-by-year earnings quality comparison for Icure Pharmaceutical Incorporation. For live market cap and the full company financial profile, see market cap of Icure Pharmaceutical Incorporation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -689.55x | ₩-17.05 Billion | ₩24.73 Million | ▼ -33240.2% |
| 2017 | 2.08x | ₩1.12 Billion | ₩537.95 Million | — |